WuXi PharmaTech’s manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operations for a high-potency active pharmaceutical ingredient (HPAPI) at its lab in Shanghai. The lab has added HPAPI processing to its portfolio of services to support process development and clinical trial supply of high-potency small molecules at kilogram scale.   “With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi’s ability to provide...